The objective of this Technical Brief is to assess the current use of life cycle assessment (LCA) frameworks in healthcare […]
We recommend that Tibsovo in combination with azacitidine be reimbursed by public drug plans for the treatment of adult patients
Women make up over half of the U.S. population, yet research on women’s health conditions, including those that are female
Vital Statistics Rapid Release Reports are based on the current flow of vital statistics data from state vital records offices
Canada’s Drug Agency recommends that Crysvita be reimbursed by public drug plans for the treatment of X-linked hypophosphatemia (XLH) in
This rapid review examines the clinical efficacy, effectiveness, and safety of BRAF and MEK inhibitors as a treatment for patients
This rapid review updates the evidence for early biologic treatment versus conventional step-up therapy for patients with luminal Crohn disease,
Registration No: 771800548 Contact Number : +91-8249516996
